Colon Carcinoma, Thyroid Cancer, Nonmedullary
Conditions
Brief summary
Tumor-related inflammation is one of the hallmarks of cancers in general. Innate immunity specifically is a common denominator which is involved in the pathogenesis of both thyroid carcinoma and colon carcinoma. To improve the patient's outcome and identify novel therapeutic targets, one needs a deeper understanding of the tumor-induced changes in the bone marrow myeloid progenitor cells. Furthermore, treatment of these cells by nanoparticles or other agents that induce a program of 'trained immunity' may be a novel way to re-educate myeloid cells and their bone marrow progenitors in thyroid carcinoma patients. Lastly, the investigators expect that this approach could be effective also in other cancers of which colon carcinoma is here proposed as an additional model. The investigators hypothesize that by exposing myeloid cells or their progenitors to various agents that induce trained immunity (e.g. high-density-lipoprotein-methylene diphosphonate nanoparticles, recombinant and synthetic cytokines), these immune cells will undergo functional reprogramming to induce a tumor-suppressive phenotype. In the future, this could be explored as a novel immunotherapy for tumors that are refractory to conventional treatment.
Interventions
no intervention will take place
Sponsors
Radboud University Medical Center
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least 18 years old and mentally competent * Newly diagnoses non-medullary thyroid carcinoma or colon carcinoma that is therapy naïve * Planned to receive conventional treatment for the malignancy by surgery
Exclusion criteria
* Mentally incompetent * Pregnant or breastfeeding * Known inflammation or infectious disease or an immunosuppressive status * Using medication interfering with the immune system * Reduced platelets counts or other conditions associated with an increased risk of bleeding * Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas) * Previous anti-cancer treatment, such as chemotherapy, radiotherapy or surgical removal or the primary tumor * Serious psychiatric pathology * A self-reported alcohol consumption of \>21 units per week
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Levels of pro-inflammatory cytokines en chemokines | After 7 days. | Levels of pro-inflammatory cytokines en chemokines such as tumor necrosis factor-alfa,interleukin(IL)-1beta and IL-6 will be measured (pg/miliLiter) before and after induction of trained immunity. This will happen after 1 and after 7 days. These will be measured using ELISA. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Age of subjects | At baseline | Age in years of subjects |
| Length of subjects | At baseline | Length in meters of subjects |
| Weight of subjects | Through study completion, an average of 1 year | Weight in kilograms of subjects |
| Thyroid stimulating hormone | At baseline | Levels of thyroid stimulating hormone (TSH), measured in mili unit/Liter. Only measured in the patients with thyroid carcinoma. |
| Carcino-embryonal antigen | At baseline | Levels of carcino-embryonal antigen (CEA), measured in ug/Liter. Only measured in patients with colon carcinoma. |
Countries
Netherlands
Outcome results
None listed